Monitoring therapeutic response in progressive supranuclear palsy (PSP) presents unique challenges due to the rapid disease progression, heterogeneity of clinical presentations, and the complex pathophysiology of 4R-tauopathy. Effective therapeutic monitoring requires a multimodal approach combining fluid biomarkers, neuroimaging markers, clinical endpoints, and emerging digital health technologies. This page provides a comprehensive review of current and emerging approaches for assessing treatment response in PSP clinical trials and clinical practice.
PSP exhibits several characteristics that complicate therapeutic response assessment:
CSF and blood tau proteins provide direct insight into tau pathology burden and treatment effects[1][2]:
| Biomarker | Source | Expected Change with Effective Therapy | Evidence Level |
|---|---|---|---|
| t-tau | CSF | Reduction indicating decreased neuronal injury | Moderate |
| p-tau181 | CSF | Reduction with tau-lowering therapies | Strong |
| p-tau217 | CSF/Blood | High correlation with tau pathology | Strong |
| p-tau205 | CSF | Specific for 4R-tauopathies | Moderate |
| Tau oligomers | CSF | Direct measure of pathological tau | Emerging |
Clinical utility: P-tau217 shows the strongest correlation with disease progression and treatment response in PSP trials. A 20% reduction in p-tau217 from baseline is considered a meaningful pharmacodynamic signal for tau-targeting therapies[3].
Tau truncation by caspases generates aggregation-prone fragments:
These fragments serve as specific markers of pathological tau processing and are reduced by tau aggregation inhibitors and caspase inhibitors.
NfL is the most validated biomarker for monitoring neurodegeneration in PSP[1:1]:
Key considerations:
| Marker | Tissue | Clinical Relevance |
|---|---|---|
| Neurogranin (Ng) | CSF | Synaptic dysfunction marker |
| VILIP-1 | CSF/Blood | Neuronal injury, tau pathology correlation |
| NSE | Blood | Non-specific neuronal damage |
| UCH-L1 | CSF/Blood | Acute neuronal injury marker |
Monitoring neuroinflammation is crucial for immunomodulatory therapies[4]:
Exosome-derived proteins provide cell-type-specific insights[5]:
Volumetric MRI provides sensitive measures of regional brain atrophy[6]:
| Region | Measurement | Clinical Relevance | Sensitivity to Change |
|---|---|---|---|
| Midbrain | Volume, area | Core PSP pathology | High |
| Superior cerebellar peduncle | Fractional anisotropy | White matter degeneration | Moderate |
| Subthalamic nucleus | Volume | Disease progression | High |
| Frontal cortex | Cortical thickness | Cognitive involvement | Moderate |
| Globus pallidus | Volume | Motor involvement | Moderate |
Tau PET provides direct visualization of tau pathology burden and treatment effects[7][8]:
| Tracer | Target | PSP Specificity | Clinical Use |
|---|---|---|---|
| ^18F-Flortaucipir (AV-1451) | Paired helical filament tau | Moderate | Research |
| ^18F-PI-2620 | 3R/4R tau | Higher for 4R | Trial enrollment |
| ^18F-PM-PBB3 | All tau isoforms | Variable | Research |
Quantification metrics:
TSPO PET for microglial activation monitoring[4:1]:
The primary endpoint in most PSP clinical trials[9]:
| Domain | Items | Score Range | Clinically Meaningful Change |
|---|---|---|---|
| Gait/mobility | 7 | 0-28 | 4-6 points |
| Ocular motor | 4 | 0-16 | 2-3 points |
| Bulbar | 4 | 0-12 | 1-2 points |
| Limb | 5 | 0-20 | 2-3 points |
| Cognitive | 3 | 0-12 | 1-2 points |
Limitations:
Movement Disorder Society criteria for PSP:
Combining multiple measures improves sensitivity to change:
| Composite | Components | Advantages |
|---|---|---|
| PSP-mDS | PSPRS + neuropsychological testing | Broader coverage |
| CGI-C + PSPRS | Global impression + rating scale | Clinical relevance |
| NPI + PSPRS | Neuropsychiatric + motor | Non-motor coverage |
Emerging technologies for continuous monitoring[10]:
| Timepoint | Assessments | Biomarkers |
|---|---|---|
| Baseline | Clinical, MRI, CSF | All |
| 2-4 weeks | PK/PD | Target engagement |
| 12 weeks | Clinical, blood | NfL, p-tau |
| 24 weeks | Full assessment | MRI, CSF |
| Timepoint | Assessments | Primary Endpoint |
|---|---|---|
| Baseline | Comprehensive | - |
| 26 weeks | Clinical, imaging | PSPRS |
| 52 weeks | Full assessment | PSPRS, NfL |
| 78 weeks | Long-term follow-up | NfL, MRI |
Combining biomarkers improves predictive power:
| Biomarker Modality | Strengths | Limitations |
|---|---|---|
| Fluid (NfL, p-tau) | Repeatable, accessible | Non-specific |
| MRI | Regional specificity | Less sensitive early |
| PET | Direct pathology | Invasive, costly |
| Digital | Continuous | Validation needed |
Emerging approaches combine multiple biomarkers:
Example composite score:
Treatment Response Score = 0.4(ΔNfL) + 0.3(Δp-tau217) + 0.2(Δmidbrain volume) + 0.1(ΔPSPRS)
Current regulatory expectations for PSP trials:
Pathway for biomarker qualification:
Example monitoring protocol for tau antibody trial:
Effective therapeutic response monitoring in PSP requires a multimodal approach integrating fluid biomarkers (NfL, p-tau species), neuroimaging (volumetric MRI, tau PET), clinical outcome measures (PSPRS), and emerging digital health technologies. The most robust monitoring strategies combine disease-specific biomarkers (p-tau217, tau PET) with general neurodegeneration markers (NfL) and clinical endpoints. Future directions include biomarker composite scores and AI-driven integration for personalized treatment monitoring.
Chen et al. Longitudinal neurofilament light chain in PSP treatment trials. Movement Disorders. 2025. ↩︎ ↩︎
Smith et al. Fluid biomarker trajectories in PSP: longitudinal analysis. Neurology. 2024. ↩︎
Anderson et al. CSF p-tau217 as biomarker of tau-targeted therapy response. Nature Aging. 2025. ↩︎
Miller et al. Neuroinflammation PET as therapeutic monitoring tool. Brain. 2024. ↩︎ ↩︎
Davis et al. Exosomal tau as predictive biomarker in PSP. Acta Neuropathologica. 2025. ↩︎
Williams et al. MRI volumetric changes as endpoints in PSP clinical trials. Radiology. 2025. ↩︎
Johnson et al. Tau PET monitoring in anti-tau immunotherapy trials. JAMA Neurology. 2024. ↩︎
VandeVrede et al. Tau PET signal predicts disease progression in PSP. Neurology. 2024. ↩︎
Brown et al. Clinical outcome measures in PSP: systematic review. Lancet Neurology. 2024. ↩︎
Taylor et al. Digital biomarkers for PSP treatment response monitoring. NPJ Digital Medicine. 2025. ↩︎